Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High-affinity CD16-expressing natural killer cell therapy - ImmunityBio

Next Previous
X
Search
Drug Profile

High-affinity CD16-expressing natural killer cell therapy - ImmunityBio

Alternative Names: CD-16 NK-92 cells; haNK; High affinity natural killer cells - ImmunityBio; NK-92 [CD16.158V, ER IL-2]

Latest Information Update: 06 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NantKwest
  • Developer ImmunityBio
  • Class Antineoplastics; Cell adhesion molecules; Cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I/II Colorectal cancer; Liver cancer; Pancreatic cancer; Squamous cell cancer; Triple negative breast cancer
  • No development reported Head and neck cancer; HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 01 Aug 2024 ImmunityBio terminates a QUILT-3.080 phase I/II trial in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (IV) prematurely (NCT03586869)
  • 22 May 2024 NantKwest terminates a phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)
  • 16 Jan 2024 ImmunityBio terminates a Phase-I/II clinical trials in Triple negative Breast cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (SC) prematurely (NCT03387085)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top